Axalta Guides 4Q Adjusted EBITDA to $254M-$264M
AXTA sits 34% above its 52-week low of $24.937.
Summary
Axalta put a $254 million to $264 million range on fourth-quarter adjusted EBITDA, its first explicit forward number for the quarter. The midpoint sits below the record $305 million adjusted EBITDA it posted in Q2, so the guide implies sequential softening rather than a step-up. For the full year 2026, the company sees adjusted EBITDA of $1.1 billion to $1.11 billion. Context matters here: the company is mid-flight in the all-share merger of equals with AkzoNobel, with EU clearance expected on remedies and UK CMA still in a Phase 1 review, and Axalta has already agreed to divest its North American Building Products business to satisfy regulators. Merger costs have been running through the P&L, with $35 million in Q2 alone, so the adjusted figure strips out charges that still hit reported earnings. The range is the number to hold management to when the quarter closes.
At the time of this announcement, AXTA was trading at $33.40 on NYSE in the Manufacturing sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $24.94 to $38.61. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.